Cartalax

Cartalax (Ala-Glu-Asp) is a synthetic tripeptide developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as part of the bioregulator peptide program. It belongs to a class of ultra-short peptides (2-4 amino acids) that Khavinson's group has investigated for tissue-specific regulatory effects over several decades. Cartalax was designed to target cartilage and musculoskeletal tissue, with the aim of preserving cartilage integrity and promoting chondrocyte function during aging.

The bioregulator peptide concept posits that short peptides can interact directly with DNA through sequence-specific binding to the minor groove, influencing gene expression without requiring membrane receptor activation. This is a non-conventional mechanism for peptide action and remains an area of active research, primarily within Russian academic institutions. Cartalax is part of a larger family of Khavinson peptides that includes Epitalon (AEDG), Pinealon (EDR), and others, each claimed to have tissue-specific tropism.

Cartalax's proposed mechanism of action involves direct interaction with DNA in chondrocytes and cartilage progenitor cells. According to the bioregulator peptide model, the Ala-Glu-Asp sequence binds to complementary nucleotide sequences in gene promoter regions, modulating transcription of cartilage-specific genes. In vitro studies have shown that Cartalax increases expression of collagen type II and aggrecan — the major structural components of hyaline cartilage — while reducing expression of matrix metalloproteinase-13 (MMP-13), a collagenase responsible for cartilage degradation in osteoarthritis.

The peptide also influences cell cycle regulators, affecting Ki-67 (proliferation marker) and p53 (apoptosis/senescence regulator) expression in ways that favor cellular renewal over senescence. Whether these effects result from direct DNA interaction or from more conventional signaling mechanisms (such as interaction with cell surface peptide transporters or intracellular targets) has not been definitively resolved. The extremely small size of Cartalax (319 Da) allows it to cross cell membranes readily, which is consistent with either mechanism.